PL2403845T3 - Ulepszony sposób - Google Patents

Ulepszony sposób

Info

Publication number
PL2403845T3
PL2403845T3 PL10707950T PL10707950T PL2403845T3 PL 2403845 T3 PL2403845 T3 PL 2403845T3 PL 10707950 T PL10707950 T PL 10707950T PL 10707950 T PL10707950 T PL 10707950T PL 2403845 T3 PL2403845 T3 PL 2403845T3
Authority
PL
Poland
Prior art keywords
improved process
improved
Prior art date
Application number
PL10707950T
Other languages
English (en)
Inventor
Vinayak Govind Gore
Vinay Kumar Shukla
Shreyas Shrikant Bhandari
Suresh Hasbe
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of PL2403845T3 publication Critical patent/PL2403845T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
PL10707950T 2009-03-02 2010-03-01 Ulepszony sposób PL2403845T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16
EP10707950.1A EP2403845B1 (en) 2009-03-02 2010-03-01 Improved process
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (1)

Publication Number Publication Date
PL2403845T3 true PL2403845T3 (pl) 2014-09-30

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10707950T PL2403845T3 (pl) 2009-03-02 2010-03-01 Ulepszony sposób

Country Status (16)

Country Link
US (1) US8946265B2 (pl)
EP (1) EP2403845B1 (pl)
JP (1) JP5727944B2 (pl)
CN (1) CN102414196A (pl)
AU (1) AU2010220204B2 (pl)
CA (1) CA2753241C (pl)
CY (1) CY1115376T1 (pl)
DK (1) DK2403845T3 (pl)
ES (1) ES2487215T3 (pl)
HR (1) HRP20140686T1 (pl)
NZ (1) NZ595492A (pl)
PL (1) PL2403845T3 (pl)
PT (1) PT2403845E (pl)
SI (1) SI2403845T1 (pl)
SM (1) SMT201400100B (pl)
WO (1) WO2010100476A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
ES2727705T3 (es) 2010-03-08 2019-10-18 Natco Pharma Ltd Forma I de lenalidomida anhidra
MX352824B (es) 2010-06-16 2017-12-11 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
WO2013012485A2 (en) 2011-07-19 2013-01-24 Amplio Pharma, Llc Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
EP2968309A4 (en) 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9808450B2 (en) 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
US20170107193A1 (en) * 2014-04-26 2017-04-20 Shilpa Medicare Limited Crystalline lenalidomide process
US10392364B2 (en) 2014-08-11 2019-08-27 Avra Laboratories Pvt. Ltd. Process for synthesis of lenalidomide
WO2016026785A1 (en) * 2014-08-19 2016-02-25 Synthon B.V. Process for making crystalline form a of lenalidomide
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
EP3393457A1 (en) * 2015-12-22 2018-10-31 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
JP2020535192A (ja) * 2017-09-27 2020-12-03 バイオコン・リミテッド レナリドミドの結晶形
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体（上海）有限公司 一种制备来那度胺的方法
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
ES2437592T3 (es) 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
AU2008240078B2 (en) 2007-04-16 2012-10-25 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
AU2008337304A1 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited HPLC method for analysing clopidogrel
AU2009223014A1 (en) 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
US20110263649A1 (en) 2008-11-03 2011-10-27 Generics [Uk] Limited Crystalline form of lenalidomide and a process for its preparation
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
CN102414196A (zh) 2012-04-11
ES2487215T3 (es) 2014-08-20
JP5727944B2 (ja) 2015-06-03
SI2403845T1 (sl) 2014-09-30
SMT201400100B (it) 2014-11-10
US8946265B2 (en) 2015-02-03
CA2753241A1 (en) 2010-09-10
NZ595492A (en) 2013-07-26
HRP20140686T1 (hr) 2014-09-26
EP2403845B1 (en) 2014-04-30
EP2403845A2 (en) 2012-01-11
AU2010220204A1 (en) 2011-10-20
CA2753241C (en) 2015-06-16
CY1115376T1 (el) 2017-01-04
PT2403845E (pt) 2014-08-04
JP2012519207A (ja) 2012-08-23
US20120071509A1 (en) 2012-03-22
AU2010220204B2 (en) 2015-10-08
WO2010100476A3 (en) 2011-06-16
DK2403845T3 (da) 2014-08-04
WO2010100476A2 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
GB0918069D0 (en) Process
SI2403845T1 (sl) Izboljšani postopek
GB0919117D0 (en) Process
GB0901254D0 (en) Process
GB0919385D0 (en) Process
GB0907879D0 (en) Process
GB0912255D0 (en) Process
GB0918830D0 (en) Process
GB0905998D0 (en) Process
GB0906191D0 (en) Process
GB0914338D0 (en) Improved process
GB0901444D0 (en) Method
GB0914500D0 (en) Process
GB0901817D0 (en) Process
GB0912254D0 (en) Process
GB0901816D0 (en) Process
GB0918613D0 (en) Process
GB0914572D0 (en) Process
GB0902286D0 (en) Process
ZA201108937B (en) Process
GB0915106D0 (en) Process
GB0913318D0 (en) Process
GB0906031D0 (en) Process
GB0903956D0 (en) Process
GB0901822D0 (en) Process